Sugi Predict

Sugi Predict / Compounds / SCHEMBL600192

SCHEMBL600192

SCHEMBL600192

C#CCCC(C)(N)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GGT1 P19440 1/20 0.50
▸ ARG1 P05089 1/20 0.46
▸ ARG2 P78540 1/20 0.46
▸ BLM P54132 2/20 0.36
▸ CYP1A2 P05177 3/20 0.34
▸ MAPT P10636 2/20 0.34
▸ HSD17B10 Q99714 2/20 0.34
▸ CYP2D6 P10635 2/20 0.34
▸ CYP2C19 P33261 2/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ ALDH1A1 P00352 4/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ HPGD P15428 2/20 0.33
▸ PTGS2 P35354 2/20 0.33
▸ USP2 O75604 1/20 0.33
▸ EGFR P00533 1/20 0.33
▸ FYN P06241 1/20 0.33
▸ POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL600191 1.00 GGT1 (0.50) GGT1ARG1ARG2BLMCYP1A2
SCHEMBL602005 1.00 GGT1 (0.50) GGT1ARG1ARG2BLMCYP1A2
SCHEMBL600647 0.88 ARG1 (0.52) GGT1ARG1ARG2BLMCYP1A2
SCHEMBL600648 0.88 ARG1 (0.52) GGT1ARG1ARG2BLMCYP1A2
SCHEMBL601002 0.88 ARG1 (0.52) GGT1ARG1ARG2BLMCYP1A2
SCHEMBL599814 0.86 ARG1 (0.55) GGT1ARG1ARG2BLMCYP1A2
SCHEMBL601232 0.86 ARG1 (0.55) GGT1ARG1ARG2BLMCYP1A2
SCHEMBL599813 0.86 ARG1 (0.55) GGT1ARG1ARG2BLMCYP1A2
SCHEMBL600737 0.84 ARG1 (0.53) GGT1ARG1ARG2BLMCYP1A2
SCHEMBL602186 0.84 ARG1 (0.53) GGT1ARG1ARG2BLMCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114729006-A Cyclic peptide compounds having Kras inhibitory activity 中外制药株式会社 2022-07-08 — — CN claimed
EP-2564863-B1 Triazole linked macrocyclic peptides AILERON THERAPEUTICS INC (US) 2017-08-23 — — EP claimed
EP-2564862-B1 Substituted amino acids for preparing triazole linked macrocyclic peptides AILERON THERAPEUTICS INC (US) 2017-08-02 — — EP claimed
CN-101663044-B Triazole macrocycle systems AILERON THERAPEUTICS INC 2014-07-23 — — CN claimed
US-8637686-B2 Triazole macrocycle systems AILERON THERAPEUTICS, INC. (US) 2014-01-28 — — US claimed
EP-2564863-A2 Triazole linked macrocyclic peptides Aileron Therapeutics, Inc. (US) 2013-03-06 — — EP claimed
EP-2564862-A2 Triazole linked macrocyclic peptides Aileron Therapeutics, Inc. (US) 2013-03-06 — — EP claimed
EP-2114428-B1 Triazole linked macrocyclic peptides AILERON THERAPEUTICS INC (US) 2012-10-31 — — EP claimed
US-20110263815-A1 TRIAZOLE MACROCYCLE SYSTEMS AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) 2011-10-27 — — US claimed
US-7981999-B2 Peptidomimetics; kits; macrocyclization AILERON THERAPEUTICS, INC. (US) 2011-07-19 — — US claimed
CN-101663044-A triazole macrocycle systems AILERON THERAPEUTICS INC 2010-03-03 — — CN claimed
EP-2114428-A2 TRIAZOLE MACROCYCLE SYSTEMS Aileron Therapeutics, Inc. (US) 2009-11-11 — — EP claimed
US-20080262200-A1 Triazole Macrocycle Systems AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) 2008-10-23 — — US claimed
WO-2008104000-A2 TRIAZOLE MACROCYCLE SYSTEMS AILERON THERAPEUTICS, INC. (US) 2008-08-28 — — WO claimed
CN-114729006-A Cyclic peptide compounds having Kras inhibitory activity 中外制药株式会社 2022-07-08 — — CN disclosed
US-20190292224-A1 TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES AILERON THERAPEUTICS, INC. 2019-09-26 — — US disclosed
US-20190225650-A1 PEPTIDOMIMETIC MACROCYCLES AND USE THEREOF IN REGULATING HIF1ALPHA AILERON THERAPEUTICS, INC. 2019-07-25 — — US disclosed
WO-2009099677-A2 THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES AILERON THERAPEUTICS, INC. (US) 2009-08-13 — — WO disclosed
US-20080262200-A1 Triazole Macrocycle Systems AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) 2008-10-23 — — US disclosed
WO-2008104000-A2 TRIAZOLE MACROCYCLE SYSTEMS AILERON THERAPEUTICS, INC. (US) 2008-08-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225650-A1 PEPTIDOMIMETIC MACROCYCLES AND USE THEREOF IN REGULATING HIF1ALPHA HIF1A, HIF1AN, EGLN3 GGT1 2868/4885ARG1 121/4885ARG2 29/4885
US-20080262200-A1 Triazole Macrocycle Systems FLT3, VIP, NGLY1 GGT1 3198/4885ARG1 108/4885ARG2 219/4885
US-20110263815-A1 TRIAZOLE MACROCYCLE SYSTEMS FLT3, VIP, NGLY1 GGT1 3198/4885ARG1 108/4885ARG2 219/4885
US-20190292224-A1 TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES IL33, TPR, CDC37 GGT1 2457/4885ARG1 128/4885ARG2 199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.